Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use.

OBJECTIVE The association between osteoarthritis (OA) and fractures remains unclear. OA patients have increased bone mass, but no corresponding decrease in fracture rate. This study was undertaken to determine the fracture rates in patients with hip OA undergoing a total hip replacement (THR), as compared with disease-free controls, and to assess the association between bisphosphonate use and postsurgery fracture risk. METHODS We conducted a population-based parallel-cohorts study. All patients in the UK General Practice Research Database undergoing a THR for hip OA between 1986 and 2006 constituted the exposed cohort (n = 14,133). Five disease-free controls were matched with each patient by age, sex, and practice site. Subjects were followed up for 5 years before and after surgery. Fracture rates and rate ratios (RRs) were estimated using Poisson regression. In addition, bisphosphonate use was identified among patients undergoing THR, and the data, stratified by the presence or absence of a previous fracture and by treatment propensity score, were assessed using fitted Cox models to study the effect of bisphosphonate use on the risk of fracture postsurgery. RESULTS Patients undergoing a THR had a similar fracture risk as that in controls in the 5 years before THR, but had higher rates postsurgery, which peaked at years 2.5-5 (adjusted RR 1.24, 95% confidence interval [95% CI] 1.02-1.52). Use of bisphosphonates lowered the fracture risk among THR patients who received bisphosphonates as primary prevention (hazard ratio [HR] 0.56, 95% CI 0.38-0.82) and also among THR patients who had experienced a previous osteoporotic fracture (HR 0.48, 95% CI 0.23-0.99). CONCLUSION This study identified a 25% increase in fracture risk at 2.5-5 years postsurgery among patients undergoing a THR. Bisphosphonate use reduced the post-THR risk of fracture when administered both as primary prevention and as secondary prevention, by 44% and 52%, respectively. This must be further confirmed in randomized controlled trials.

[1]  B. Morrey.  Changes in hip fracture rate before and after total knee replacement due to osteoarthritis: a population-based cohort study , 2011 .

[2]  C. Cooper,et al.  Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis , 2011, Osteoporosis International.

[3]  Tjeerd P van Staa,et al.  Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. , 2010, Bone.

[4]  H. Berg,et al.  Muscle strength, gait, and balance in 20 patients with hip osteoarthritis followed for 2 years after THA , 2010, Acta orthopaedica.

[5]  R. Francis,et al.  The prevalence of osteoporosis in patients with severe hip and knee osteoarthritis awaiting joint arthroplasty. , 2010, Age and ageing.

[6]  J. Shuhaiber,et al.  The influence of preoperative use of ventricular assist devices on survival after heart transplantation: propensity score matched analysis , 2010, BMJ : British Medical Journal.

[7]  A J Price,et al.  Temporal trends in hip and knee replacement in the United Kingdom: 1991 to 2006. , 2010, The Journal of bone and joint surgery. British volume.

[8]  Frank de Vries,et al.  Risk of Hip/Femur Fracture After Stroke: A Population-Based Case-Control Study , 2009, Stroke.

[9]  Postural balance during quiet standing in patients with total hip arthroplasty with large diameter femoral head and surface replacement arthroplasty. , 2009, Archives of physical medicine and rehabilitation.

[10]  H. Berg,et al.  Persisting muscle atrophy two years after replacement of the hip. , 2009, The Journal of bone and joint surgery. British volume.

[11]  Shawn Garbedian,et al.  Systematic Review of the Prevalence of Radiographic Primary Hip Osteoarthritis , 2009, Clinical orthopaedics and related research.

[12]  F. Prince,et al.  Gait patterns after total hip arthroplasty and surface replacement arthroplasty. , 2009, Archives of physical medicine and rehabilitation.

[13]  I. Arostegui,et al.  Prevalence of knee and hip osteoarthritis and the appropriateness of joint replacement in an older population. , 2008, Archives of internal medicine.

[14]  A. Grauer,et al.  Effects of risedronate on fracture risk in postmenopausal women with osteopenia , 2007, Osteoporosis International.

[15]  Elliott S Fisher,et al.  Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. , 2007, JAMA.

[16]  Peter Croft,et al.  Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. , 2007, The British journal of general practice : the journal of the Royal College of General Practitioners.

[17]  T. Spector,et al.  Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. , 2006, Arthritis and rheumatism.

[18]  Frank de Vries,et al.  Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. , 2006, International journal of epidemiology.

[19]  C. Cooper,et al.  Knee pain, knee osteoarthritis, and the risk of fracture. , 2006, Arthritis and rheumatism.

[20]  Ping Li,et al.  Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding , 2005, BMJ : British Medical Journal.

[21]  T. Spector,et al.  Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] , 2005, Arthritis research & therapy.

[22]  David Felson,et al.  The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. , 2004, Arthritis and rheumatism.

[23]  A. Dans,et al.  Relative risk reduction , absolute risk reduction and number needed to treat , 2022 .

[24]  P. Royston.  Multiple Imputation of Missing Values , 2004 .

[25]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[26]  A. Hofman,et al.  Osteoarthritis of the knee is associated with vertebral and nonvertebral fractures in the elderly: the Rotterdam Study. , 2003, Arthritis and rheumatism.

[27]  Paul R Rosenbaum,et al.  Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity Scores , 2002, Annals of Internal Medicine.

[28]  C. Cooper,et al.  Utility of medical and drug history in fracture risk prediction among men and women. , 2002, Bone.

[29]  C. Cooper,et al.  Epidemiology of fractures in England and Wales. , 2001, Bone.

[30]  J. Williams,et al.  IN A POPULATION-BASED CASE-CONTROL STUDY , 2001 .

[31]  C. Cooper,et al.  Use of Inhaled Corticosteroids and Risk of Fractures , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[33]  L Abenhaim,et al.  The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results , 2000, Pharmacoepidemiology and drug safety.

[34]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[35]  S. Cummings,et al.  Osteoarthritis and risk of falls, rates of bone loss, and osteoporotic fractures. Study of Osteoporotic Fractures Research Group. , 1999, Arthritis and rheumatism.

[36]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[37]  T. Spector,et al.  The association between osteoarthritis and osteoporotic fracture: the Chingford Study. , 1996, British journal of rheumatology.

[38]  S. Cummings,et al.  Radiographic osteoarthritis of the hip and bone mineral density. The Study of Osteoporotic Fractures Research Group. , 1995, Arthritis and rheumatism.

[39]  S. Lord,et al.  Osteoarthritis, bone density, postural stability, and osteoporotic fractures: a population based study. , 1995, The Journal of rheumatology.

[40]  Daniel Levy,et al.  Bone mineral density and knee osteoarthritis in elderly men and women. The Framingham Study. , 1993, Arthritis and rheumatism.

[41]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .